Venetoclax-based low-intensity chemotherapy in the salvage treatment of relapsed/refractory T-cell acute lymphoblastic leukemia.

ABSTRACT: T-cell acute lymphoblastic leukemia (T-ALL) is a very rare hematological malignancy with a poor prognosis. Conventional cytotoxic regimens have exhibited poor tolerance in clinical practice. Preclinical researches, sparse case reports, and small-scale single-arm studies showed that venetoclax-based salvage chemotherapy had a promising clinical efficacy. However, to date, no case-control studies or prospective trials in relapsed/refractory T-ALL have been conducted to compare venetoclax-based therapies with conventional cytotoxic chemotherapies, owing to the disease's rarity and the challenging treatment landscape. We conducted a retrospective case-cohort study comparing venetoclax-based low-intensity chemotherapy with conventional cytotoxic chemotherapies in the treatment of relapsed/refra

SUBMITTER: Xu F 

PROVIDER: S-EPMC11965153 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature